دورية أكاديمية

Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma

التفاصيل البيبلوغرافية
العنوان: Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma
المؤلفون: Xiao-Han Zhao, Hong-Mei Gao, Jing-Yuan Wen, He-Song Wang, Luan-Ying Wu, Chun-Yang Song, Wen-Zhao Deng, Shu-Chai Zhu, Wen-Bin Shen
المصدر: Discover Oncology, Vol 14, Iss 1, Pp 1-11 (2023)
بيانات النشر: Springer, 2023.
سنة النشر: 2023
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Immunotherapy, Radiotherapy, Chemotherapy, Esophageal squamous cell carcinoma, Prognosis, Treatment-related adverse events, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Abstract Objective This study was designed to investigate the efficacy and prognostic factors for immune checkpoint inhibitors (ICIs) combined with or without radio(chemo)therapy and to evaluate their toxicity in patients with locally advanced or recurrent/metastatic esophageal squamous cell carcinoma (LA/RM ESCC). Methods In this study, 198 patients with locally advanced or recurrent/metastatic (LA/RM) ESCC who received ICIs combined with or without radiotherapy/chemotherapy in the Department of Radiotherapy of the Fourth Hospital of Hebei Medical University were retrospectively analyzed. Univariate and multivariate analyses were performed to determine the prognostic factors for overall survival (OS) and progression free survival (PFS). The factors affecting treatment response and the occurrences of treatment-related adverse events (trAEs) were analyzed. Results The median OS and PFS were 30.4 months (95% confidence interval [CI] 15.1–45.7 months) and 15.3 months (95% CI 12.8–17.8 months), respectively. Univariate and multivariate analysis showed that the number of ICI cycles, the intervention of radiotherapy and dysphagia were independent factors affecting OS (Hazard ratio [HR] = 0.39, 2.043 and 0.365, respectively; P = 0.018, 0.001 and 0.032, respectively). The intervention of radiotherapy was an independent factor for PFS (hazard ratio [HR] = 18.149, P = 0.013). The median OS and PFS for patients who had complete response and partial response (Objective response, ORR) were 50.8 months (95% CI 25.8–75.7 months) and 20.5 months (95% CI 14.1–27.0), respectively, which were significantly higher than those in the non-ORR group (OSnon-ORR:17.5 months, 95% CI 14.0–21.0; χ2 = 13.881, P
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2730-6011
Relation: https://doaj.org/toc/2730-6011
DOI: 10.1007/s12672-023-00783-3
URL الوصول: https://doaj.org/article/3f5ce182deaf4f4fb76f2cfe2c3aa7cb
رقم الأكسشن: edsdoj.3f5ce182deaf4f4fb76f2cfe2c3aa7cb
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:27306011
DOI:10.1007/s12672-023-00783-3